MEK inhibition suppresses B regulatory cells and augments anti-tumor immunity.

摘要: Mitogen-activated protein kinase (MAPK) (MEK) is an integral component of the RAS pathway and a therapeutic target in RAS-driven cancers. Although tumor responses to MEK inhibition are rarely durable, inhibitors have shown substantial activity durable regressions when combined with systemic immunotherapies preclinical models tumors. been potentiate anti-tumor T cell immunity, but little known about effects on other immune subsets, including B cells. We show here that treatment inhibitor reduces regulatory cells (Bregs) vitro, number Bregs draining lymph nodes colorectal cancer model vivo. does not impede humoral contribute meaningfully immunity context therapy. Treatment associated improved infiltration enhanced response anti-PD1 immunotherapy. Together these data indicate may reduce while sparing function, resulting immunity.